SLNO: Soleno Company Value to Net Income

Symbol and logo of brand Soleno Therapeutics Inc (SLNO)

The lack of alternatives for Prader-Willi syndrome therapy suggests a monopoly for Soleno Therapeutics (SLNO), yet the company's median P/E shown on this GURU.Markets chart confirms volatile expectations. The value 28.20 expresses the metric's current value, while success remains dependent on FDA approval and the commercialization of DCCR. Stability is guaranteed by elite endocrinologists whose developments are supported by robust laboratory funding.

P/E Multiple: Soleno (SLNO) for 07/04/2022 - 05/30/2026

Comprehensive metric breakdowns and analytics for Soleno Therapeutics Corp (SLNO)

- price and consensus price forecast:
- market capitalization information:
Summary company analysis:Soleno Therapeutics Inc
Finished products of Soleno

Professional Capital evaluates Soleno Therapeutics (SLNO) through the lens of its exclusive patent portfolio within the rare metabolic disorders niche. By analyzing the company's P/E ratio, the investor compares the business's market value with its annual earnings to identify potential asset overvaluation or revenue decline risks, thereby confirming the fundamental stability of this highly specialized player.